AI Article Synopsis

  • The study evaluated the safety and effectiveness of administering the inactivated quadrivalent influenza vaccine (IIV4) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) together in adults aged 60 and older in China.
  • Participants were split into two groups: one received both vaccines at the same time (C group) and the other received them separately (S group). Blood samples were tested for antibody levels after vaccination.
  • Results showed that the immune response from the combined administration was comparable to the separate administration, with fewer adverse events reported in the C group, indicating that it is a safe option for older adults.

Article Abstract

The inactivated quadrivalent influenza vaccine (IIV4) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) have been administered for years and could be administered concomitantly if necessary. However, the immunogenicity and safety of the concomitant administration of these two vaccines have not been well documented, especially in the Chinese population. In this study, 480 participants aged 60 years and older were randomly assigned to the concomitant administration group (C group) or the separate administration group (S group) to receive IIV4 and PPSV23 either concomitantly or separately. Blood samples were collected before and 28 days after each vaccination. The antibodies against four influenza virus strains and twenty-three pneumococcus serotypes were tested. The results showed that the geometric mean titer (GMT) ratios (C group to S group) for the four influenza strains ranged from 0.72 to 0.95, with the lower limits of the 95% confidence intervals (CIs) ranging from 0.51 to 0.75, and the geometric mean concentration (GMC) ratios for the 23 pneumococcal serotypes ranged from 0.80 to 1.00, with the lower limits of 95% CIs ranging from 0.67 to 0.86. All values met the predefined criteria for non-inferiority. The incidence of adverse events was 0.63% in the C group and 1.56% in the S group. No serious adverse events were observed. In conclusion, the immunogenicity of the concomitant administration of IIV4 and PPSV23 was non-inferior to that of the separate administration, and the safety profile was favorable in adults aged 60 years and older in China.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11360506PMC
http://dx.doi.org/10.3390/vaccines12080935DOI Listing

Publication Analysis

Top Keywords

aged years
12
years older
12
concomitant administration
12
group group
12
immunogenicity safety
8
inactivated quadrivalent
8
quadrivalent influenza
8
influenza vaccine
8
administered concomitantly
8
23-valent pneumococcal
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!